SALVAGE SURGERY FOR ANAL CANAL CARCINOMA: LONG TERM OUTCOMES FROM A TERTIARY REFERRAL CENTRE

Awais A. Malik1, Syed H Raza1, Irfan-ul-Islam Nasir1, Muhammad F Shah1, Namra Urooj1, Tabinda Sada2, Shahid Khattak1, Aamir A Syed1

Departments of Surgical Oncology1 and Radiation Oncology2; Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan

Received: 6 December 2016, Accepted 13 March 2017

Abstract

Purpose: To analyse the outcome of salvage surgery in management of anal canal cancer.

Methodology: All patients with a diagnosis of anal canal carcinoma from 2006 to 2015 were studied. Basic demographic data was recorded. Treatment modalities used were recorded for all patients. Long term surgical outcomes were recorded. Median survival in months was recorded. All data was recorded in SPSS ver. 20.

Results: A total of 62 patients were included in the study. Median age was 51. 38 Patients had SCCa on histology and 24 had an Adenocarcinoma. 52% patients had a T4 lesion. Chemoradiotherapy was offered to 59 (95%) patients as a first line of therapy. 12 (19%) patients had a complete response. 37 (60%) patients had a partial and 10 (16%) patients had no response to chemoradiation. Salvage surgery was offered to 27 patients. Of these 21 had a curative resection. 6 had irresectable disease and underwent a colostomy only. Median overall survival for all patients was 46 months with a 5 year survival of 55%. Patients with partial response who were offered salvage surgery the 5 year survival was 40%. For patients with no response or progressive disease after chemo XRT the 5 year survival was 20%.

Conclusion: Long-term survival can be achieved in majority of patients who undergo radical salvage surgery after failed CRT for carcinoma of the anal canal.

Keywords Anal canal, adenocarcinoma, surgery, chemoradiotherapy

Introduction:

Anal Canal carcinoma is a rare malignancy with an annual reported incidence of 0.5–1.0 per 100 000 population in most Western countries [1]. SCC represents the most common subtype. No data regarding this disease is available from Pakistan. Standard treatment of these cancers was by surgical resection with poor survival outcomes of 27–71% with a high rate of local recurrence [1-4]. With the introduction of neo adjuvant chemoradiation, survival outcomes have increased to 65-90% with local recurrence rates of 10-30%. Accordingly, chemoradiotherapy has become the preferred choice of treatment and is now widely accepted [5-8], with radical surgery being reserved for patients with residual or recurrent disease [9-10].

Anal canal cancer is a relatively rare disease, and the majority of patients are cured by chemoradiation. So the published literature on the role of salvage surgery for patients with failed response to CRT is very scarce. It consists of a few small case series, collected over long time intervals [11-13]. Renehan and colleagues published the largest reported series of salvage resection, in 73 patients, and showed a 5-year survival rate of 40% [14]. The value of salvage surgery for anal canal cancer is thus debatable at present, and more data are required. Shaukat Khanum Memorial Cancer Hospital and Research Centre is a major referral center for those requiring treatment of
anal canal cancer. We have an established neo-adjuvant chemoradiation protocol for these patients. Our purpose in the present study was to describe the long-term oncological outcomes associated with resection of residual/recurrent cancers of the anal canal at our institution.

METHODOLOGY:

All patients with a diagnosis of Anal canal CA from 2006 to 2015 were studied. Basic demographic data was recorded. Treatment modalities used were recorded for all patients. Long term surgical outcomes were recorded. For survival only patients operated before 2011 were included. Median survival in months was recorded. All data was recorded in SPSS ver. 20.

RESULTS:

A total of 62 patients were included in the study. Median age was 51 (18 to 82). There were 48 males and 14 females. 38 Patients had SCCa on histology and 24 had an adenocarcinoma. 52% patients had a T4 lesion, 29% had a T3. 73% patients were node positive. 2 patients (3%) had a metastatic disease at presentation. Chemotherapy was offered to 59 (95%) patients as a first line of therapy. Radiation was also offered to 59 (95%) patients. 12 (19%) patients had a complete response. 37 (60%) patients had a partial and 10 (16%) patients had no response to chemoradiation. Surgery was offered to 27 patients. Of these 21 had a curative resection. 6 had irrectable disease and underwent a colostomy only. Median overall survival for all patients was 46 months with a 5 year survival of 55%. For patients who had a complete response overall survival was 60 months. Patient who had a partial response to Chemo XRT but did not undergo salvage surgery the survival was 40 months. However for patients with partial response who were offered salvage surgery the overall survival increased to 52 months. For patients with no response or progressive disease after chemo XRT the overall survival was 18 months. When individually compared SCC had better survival outcomes as compared to Adenocarcinoma. 17 patients had a recurrence. 4 patients had complete response. 8 patients had partial response and 5 patients had no response. 10 patients had a local recurrence while 7 patients presented with distant metastasis. 9 out of 21 patients who underwent salvage surgery did not show any recurrence.

DISCUSSION:

Anal canal cancers account for only 2% of all large bowel cancers [1,2]. With the introduction of combined CRT as the primary treatment modality, 5-year survival rates improved [6-8]. On the contrary the morbidity also decreased as more and more patients had sphincter preservation. Our results are at par with this as 65% of our patients ended up with sphincter preservation with a median overall survival of 46 months. Despite the success of combined CRT, a good proportion of patients fail treatment. Salvage chemo XRT has been advocated by some with cisplatin-containing regimens, reporting 50% survival at 4 years, whereas others have reported more disappointing results with salvage CRT. However experience with salvage surgery has been more rewarding making radical rectal resection the treatment of choice. Previous investigators have reported 5-year survival rates after salvage APR in the range of 24–53% [10-14]. We had a 5 year survival of 40% for patients who underwent salvage surgery for failed response to neo-adjuvant chemoradiation. Of the patients who were offered surgery 9 patients had persistent disease and 12 had recurrent disease. Patients with persistent disease had a slightly worse outcome as compared to those who had recurrent disease. (33 months for persistent disease vs. 36 months for recurrent disease). This finding is in agreement with what several other groups have reported [13,15]. However, others have reported no difference in survival in between the two groups [11,14]. 7/21 patients (33%) developed secondary failure. Most of these patients are either dead or are living with disease. Most of the patients did not receive adjuvant chemoradiation which supports the notion that adjuvant chemotherapy in conjunction
with salvage surgery may be warranted in selected patients.

CONCLUSION:

This study is retrospective in nature with a small patient size. Unfortunately anal canal cancer is a rare entity and it is not possible to achieve a large sample size. However, results of our study suggest that long-term survival can be achieved in majority of patients who undergo radical salvage surgery after failed CRT for carcinoma of the anal canal.

References:

6. UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR


